Replimune Appoints Veleka R. Peeples-Dyer to its Board of Directors
June 05 2023 - 08:00AM
Replimune Group, Inc. (Nasdaq: REPL), a clinical stage
biotechnology company pioneering the development of a novel
portfolio of tumor-directed oncolytic immunotherapies, today
announced the appointment of Veleka R. Peeples-Dyer to the
Company’s Board of Directors effective June 1, 2023.
“We are pleased to welcome Veleka to Replimune’s Board of
Directors,” said Philip Astley-Sparke, Chief Executive Officer of
Replimune. “Veleka is a highly accomplished life sciences
executive, experienced attorney and compliance professional with
over 24 years of her practice dedicated to the life sciences
industry assisting with building legal and compliance teams and
advising on the research, development, approval and
commercialization of products in the industry. We look forward to
working with Veleka and believe her guidance and input will
strengthen our board as we advance and anticipate commercialization
of our leading pipeline of oncolytic immunotherapies.”
Ms. Peeples-Dyer has served as a strategic enterprise leader at
leading biopharmaceutical companies serving as in-house counsel for
over 16 years and outside counsel to global life sciences clients
through her partnerships at prominent life sciences law firms,
including as the Chair of the North American Food and Drug practice
and Co-Chair of the Global Regulatory Group at Baker McKenzie, a
top ten global life sciences firm. Throughout her career in the
life sciences industry, including executive appointments as Chief
Legal Officer, Chief Compliance Officer and Corporate Secretary,
Veleka has provided business, legal and compliance advice and
counsel on a wide variety of matters, including Food and Drug
Administration (FDA) regulatory, global compliance, business
development, clinical trials, quality, manufacturing,
commercialization and other corporate matters. Ms. Peeples-Dyer is
currently on the Advisory Board of Syridex Bio, a life sciences
impact investment firm dedicated to the acceleration of health
equity through focusing on investing in therapies for diseases that
disproportionately affect underserved populations.
Ms. Peeples-Dyer holds a Bachelor’s degree in Political Science
from Hampton University and a Juris Doctor degree from the
University of South Carolina School of Law. Veleka is recognized
across the legal and life sciences arena as a leader and has
received numerous recognitions, including most recently being named
to The Top 50 Women Leaders of DC for 2023 and listed in Savoy
Magazine as 2022 Most Influential Black Executives in Corporate
America, and 2022 Most Influential Black Lawyers.
About Replimune Replimune Group, Inc.,
headquartered in Woburn, MA, was founded in 2015 with the mission
to transform cancer treatment by pioneering the development of
novel tumor-directed oncolytic immunotherapies. Replimune’s
proprietary RPx platform is based on a potent HSV-1 backbone with
payloads added to maximize immunogenic cell death and the induction
of a systemic anti-tumor immune response. The RPx platform has a
unique dual local and systemic mechanism of action (MOA) consisting
of direct selective virus-mediated killing of the tumor resulting
in the release of tumor derived antigens and altering of the tumor
microenvironment (TME) to ignite a strong and durable systemic
response. This MOA is expected to be synergistic with most
established and experimental cancer treatment modalities, and, with
an attractive safety profile the RPx platform has the versatility
to be developed alone or combined with a variety of other treatment
options. For more information, please visit www.replimune.com.
Forward Looking Statements This press release
contains forward looking statements within the meaning of Section
27A of the Securities Act of 1933, as amended, and Section 21E of
the Securities Exchange Act of 1934, as amended, including
statements regarding the design and advancement of our clinical
trials, the timing and sufficiency of our clinical trial outcomes
to support potential approval of any of our product candidates, our
goals to develop and commercialize our product candidates, patient
enrollments in our existing and planned clinical trials and the
timing thereof, and other statements identified by words such as
“could,” “expects,” “intends,” “may,” “plans,” “potential,”
“should,” “will,” “would,” or similar expressions and the negatives
of those terms. Forward-looking statements are not promises or
guarantees of future performance, and are subject to a variety of
risks and uncertainties, many of which are beyond our control, and
which could cause actual results to differ materially from those
contemplated in such forward-looking statements. These factors
include risks related to our limited operating history, our ability
to generate positive clinical trial results for our product
candidates, the costs and timing of operating our in-house
manufacturing facility, the timing and scope of regulatory
approvals, changes in laws and regulations to which we are subject,
competitive pressures, our ability to identify additional product
candidates, political and global macro factors including the impact
of the coronavirus as a global pandemic and related public health
issues, and other risks as may be detailed from time to time in our
Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q and
other reports we file with the Securities and Exchange Commission.
Our actual results could differ materially from the results
described in or implied by such forward-looking statements.
Forward-looking statements speak only as of the date hereof, and,
except as required by law, we undertake no obligation to update or
revise these forward-looking statements.
Investor Inquiries Chris BrinzeyICR
Westwicke339-970-2843chris.brinzey@westwicke.com
Media InquiriesArleen GoldenbergVice President,
Corporate Communications 917-548-1582media@replimune.com
Replimune (NASDAQ:REPL)
Historical Stock Chart
From Nov 2023 to Dec 2023
Replimune (NASDAQ:REPL)
Historical Stock Chart
From Dec 2022 to Dec 2023